Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 8INDUSTRY 3NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2

Conditions

Leukemia 4Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Biphenotypic, Acute 2Recurrence 1Colorectal Neoplasms 1

Interventions

Azacitidine 142Cytarabine 109venetoclax 94fludarabine 35Daunorubicin 34Decitabine 32Idarubicin 26gilteritinib 24Cyclophosphamide 21quizartinib 15midostaurin 15Mitoxantrone 14Etoposide 14Granulocyte Colony-Stimulating Factor 12Gemtuzumab 11CPX-351 11decitabine and cedazuridine drug combination 10Drug Therapy 10cc-486 9Filgrastim 9Clofarabine 9ivosidenib 8Injections 8Dexamethasone 8pevonedistat 7fludarabine phosphate 7AP 1903 reagent 7posaconazole 6magrolimab 6glasdegib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid, Acute × revumenib × Clear all
NCT07211958 2026-05-20

REVEAL-ND NPM1

Syndax Pharmaceuticals

Phase 3 Recruiting
468 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04065399 2026-03-18

AUGMENT-101

Syndax Pharmaceuticals

Phase 1/2 Recruiting
447 enrolled 2 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05326516 2024-08-13

A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Syndax Pharmaceuticals

Phase 1 Completed
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡